Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
FARMINGDALE, N.Y., Feb. 27, 2018 -- Misonix, Inc. (Nasdaq:MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today announced that it will be participating in the Canaccord Genuity Musculoskeletal Conference held at the Sheraton hotel in New Orleans, Louisiana on Tuesday, March 6, 2018. Misonix President and Chief Executive Officer, Stavros Vizirgianakis, will be making a company presentation at 2:30 p.m. CT (3:30 p.m. ET) that day and will be available to meet with institutional investors in one-on-one meetings throughout the day.
The Misonix investor presentation is available in the “Investor Relations” section of the Company’s website at www.misonix.com. If you have questions about Misonix or are interested in conducting a conference call or meeting with management, please contact the Company’s investor relations firm, JCIR, at (212) 835-8500 or via email at [email protected].
About Misonix, Inc.
Misonix, Inc. (Nasdaq:MSON) designs, develops, manufactures and markets ultrasonic medical devices for the precise removal of hard and soft tissue, including bone removal, wound debridement and ultrasonic aspiration. Misonix is focused on leveraging its proprietary ultrasonic technology to become the standard of care in operating rooms and clinics around the world. Misonix's proprietary ultrasonic medical devices are used in a growing number of medical procedures, including spine surgery, neurosurgery, orthopedic surgery, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. At Misonix, Better Matters to us. That is why throughout the Company’s 59-year history, Misonix has maintained its commitment to medical technology innovation and the development of ultrasonic surgical products that radically improve patient outcomes. Additional information is available on the Company's web site at www.misonix.com.
Contact:
Joe Dwyer
Chief Financial Officer
Misonix, Inc.
631-927-9113
Joseph Jaffoni, Norberto Aja, Jennifer Neuman
JCIR
212-835-8500 or [email protected]
